000			01927 a2200517 4500
005			20250516093231.0
264		0	_c20121126
008			201211s 0 0 eng d
022			_a1555-8576
024	7		_a10.4161/cbt.20555 _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Chunhong
245	0	0	_aHMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells. _h[electronic resource]
260			_bCancer biology & therapy _cJul 2012
300			_a727-36 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aCell Line, Tumor _xdrug effects
650	0	4	_aCell Movement
650	0	4	_aCell Proliferation
650	0	4	_aCyclin-Dependent Kinase 2 _xmetabolism
650	0	4	_aGene Knockdown Techniques
650	0	4	_aHMGB1 Protein _xantagonists & inhibitors
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMatrix Metalloproteinase 2 _xmetabolism
650	0	4	_aMatrix Metalloproteinase 9 _xmetabolism
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aMyeloid Differentiation Factor 88 _xmetabolism
650	0	4	_aOligodeoxyribonucleotides _xpharmacology
650	0	4	_aPyruvates _xpharmacology
650	0	4	_aRNA Interference
650	0	4	_aReceptor for Advanced Glycation End Products _xgenetics
650	0	4	_aSignal Transduction
650	0	4	_aToll-Like Receptor 2 _xgenetics
650	0	4	_aToll-Like Receptor 4 _xgenetics
650	0	4	_aToll-Like Receptor 9 _xmetabolism
650	0	4	_aUp-Regulation
700	1		_aFei, Guangru
700	1		_aLiu, Zhongmin
700	1		_aLi, Qinchuan
700	1		_aXu, Zengguang
700	1		_aRen, Tao
773	0		_tCancer biology & therapy _gvol. 13 _gno. 9 _gp. 727-36
856	4	0	_uhttps://doi.org/10.4161/cbt.20555 _zAvailable from publisher's website
999			_c21802826 _d21802826